Use of Quantum Engine to Develop Multiplex Dual-Targeting CD19/CD20 CAR-T (SCM) Therapy for B-Cell Malignancies

By | 3 November 2025
  • Introduce Quantum Engine for non-viral gene therapy
  • Describe the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
  • Present preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell haematologic cancers

New Data